ArticleInternational journal of endocrinology2013
Osteoporosis associated with antipsychotic treatment in schizophrenia.
Article in International journal of endocrinology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- The neglected association between schizophrenia and bone fragility: a systematic review and meta-analyses.Translational psychiatry · 2024Pooled it
- Treatment of Comorbid Schizophrenia in an Adolescent with Osteogenesis Imperfecta: A Case Report.Turk psikiyatri dergisi = Turkish journal of psychiatry · 2026Article
- Comparing the Metabolic, Systemic, and Neuropsychiatric Impacts of Olanzapine and Clozapine in Patients with Schizophrenia.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Assessment of Monitoring and Management Practices of Antipsychotic-Induced Hyperprolactinemia at a Medical City in Riyadh, Saudi Arabia: A Retrospective Cohort Study.Current drug safety · 2025Observational
- The Association Between Antipsychotics and Bone Fragility: An Updated Comprehensive Review.Diagnostics (Basel, Switzerland) · 2024Review
- NiFe-based Prussian blue analogue nanopolygons hybridized with functionalized glyoxal polymer as a voltammetric platform for the determination of amisulpride in biological samples.Analytical and bioanalytical chemistry · 2023Article
- Bilateral atraumatic femoral neck fractures resulting from transient osteoporosis of the hip.BMJ case reports · 2022Article
- Influence of antipsychotics on metabolic syndrome risk in patients with schizophrenia.Frontiers in psychiatry · 2022Article
- The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density.Drugs · 2021Review
- Study protocol for the systematic review and meta-analyses of the association between schizophrenia and bone fragility.BMJ open · 2020Article
- Altered levels of BMD, PRL, BAP and TRACP-5b in male chronic patients with schizophrenia.Scientific reports · 2020Article
- Exposure to risperidone versus other antipsychotics and risk of osteoporosis-related fractures: a population-based study.Acta psychiatrica Scandinavica · 2020Article
- Article
- Effects of Olanzapine on Bone Mineral Density, Glucose, and Lipid Metabolism in Schizophrenia Patients.International journal of endocrinology · 2019Article
- [Somatic risks in elderly people with severe psychiatric illnesses].Zeitschrift fur Gerontologie und Geriatrie · 2018Review
- Vitamin D in patients with intellectual and developmental disability in secure in-patient services in the North of England, UK.BJPsych bulletin · 2018Article
- Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2015Article
- Chlorpromazine-Induced Hyperprolactinemia on Rat's Uterus.Iranian biomedical journal · 2015Article
- Low Bone Mass Secondary to Antipsychotic Medications.Saudi journal of medicine & medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia is one of the most common global mental diseases, with prevalence of 1%. Patients with schizophrenia are predisposed to diabetes, coronary heart disease, hypertension, and osteoporosis, than the normal. In comparison with the metabolic syndrome, for instance, there are little reports about osteoporosis which occurs secondary to antipsychotic-induced hyperprolactinaemia. There are extensive recent works of literature indicating that osteoporosis is associated with schizophrenia particularly in patients under psychotropic medication therapy. As osteoporotic fractures cause significantly increased morbidity and mortality, it is quite necessary to raise the awareness and understanding of the impact of antipsychotic-induced hyperprolactinaemia on physical health in schizophrenia. In this paper, we will review the relationship between schizophrenia, antipsychotic medication, hyperprolactinaemia, and osteoporosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.